Amalgamated Financial’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Amalgamated Financial’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$49K	Buy	+6,706	New	+$40.1K	﹤0.01%	2448

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Amalgamated Financial's PRVB Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Provention Bio, Inc. Common Stock (PRVB) in Q1 2022: 6,706 shares worth $49K. The stake represents ﹤0.01% of the portfolio and ranks #2448 among its holdings.

113 funds tracked by Wall St. Rank hold PRVB as of Q1 2022.

Amalgamated Financial held 6,706 shares of Provention Bio, Inc. Common Stock worth $49K as of Q1 2022.
Provention Bio, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Provention Bio, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2448 holding.
113 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.